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Osteoprotegerin (OPG) is a glycoprotein that acts as a decoy receptor for receptor activator of nuclear factor B
ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand. The OPG/RANKL/receptor activator
of nuclear factor B axis plays an important regulatory role in the skeletal, immune, and vascular systems. The
protective role of OPG, in animal models, against vascular calcification has not been replicated in human trials;
moreover, increased OPG levels have been consistently associated with the incidence and prevalence of coro-
nary artery disease. There seems to be some dichotomy in the role of OPG, RANKL, and tumor necrosis factor-
related apoptosis-inducing ligand in atherosclerosis and plaque stability. In this review, we integrate the findings
from some of the important studies and try to draw conclusions with a view to gaining some insight into the
complex interactions of the OPG/RANKL/receptor activator of nuclear factor B axis and tumor necrosis factor-
related apoptosis-inducing ligand in the pathophysiology of atherosclerosis. (J Am Coll Cardiol 2010;55:
2049–61) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.013O
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moronary artery disease (CAD) is the leading cause of
ortality in the Western world. Myocardial infarction (MI)
r death is the first presentation in a significant percentage
f patients with CAD. With the technological advances
eing made in the detection of silent CAD, in terms of
ssessing atherosclerotic plaque burden with coronary artery
alcium (CAC) score or identifying the percentage of
yocardium at risk with myocardial perfusion imaging,
tratification of these patients into low- and high-risk
ategories has become easier. These techniques have the
rawback of using ionizing radiation, which has its attend-
ng risks. A biomarker specific enough to be able to identify
subset of patients at increased risk of CAD would indeed
e invaluable. In this article, we focus on the evidence
egarding the utility of osteoprotegerin (OPG) and its
igands, receptor activator of nuclear factor B ligand
RANKL), and tumor necrosis factor-related apoptosis-
nducing ligand (TRAIL) as potential biomarkers of car-
iovascular disease.
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nstitute, Barts, and The London School of Medicine and Dentistry, London, United
ingdom; ‡University of Middlesex, Middlesex, United Kingdom; and the §Imperial
ollege, London, United Kingdom.(
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010, accepted March 18, 2010.verview of Bone and Vascular Biology
temporal link exists between the development of osteo-
orosis and vascular calcification, particularly marked in
ost-menopausal women and in the elderly (1–3). This link
etween the skeletal and cardiovascular systems can be
raced back to the embryonic stage of human development
hen endochondral ossification is initiated by the penetra-
ion of the cartilaginous template by a vascular bud. The
apid proliferation of chondrocytes induces hypoxia result-
ng in inhibition of the hydroxylation of the hypoxia
nducible factor 1, which then stimulates increased pro-
uction of vascular endothelial growth factor (4,5). Vascular
ndothelial growth factor induces endothelial cell prolifer-
tion, survival, and migration, resulting in the formation of
vascular network supplying oxygen and nutrients for
urther development (6).
During embryogenesis, hematopoietic cells and vascu-
ar cells are derived from a common ancestor, the
emangioblast, which is responsible for establishing the
ematopoietic stem cell niche (7,8). Osteoblasts, endo-
helial cells, and bone marrow stromal cells are also
erived from this niche (9).
Many of the bone regulatory proteins such as OPG (10),
steopontin (11), osteocalcin, bone morphogenetic protein
(12), and RANKL (10) have been shown to be present in
therosclerotic plaques in vitro and seem to be expressed by
ascular cells in vivo as well. Osteopontin protein and
RNA levels are up-regulated in atherosclerotic plaques13). Plasma osteopontin levels are also higher in patients
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Osteoprotegerin and Cardiovascular Disease May 11, 2010:2049–61with CAD compared with those
without (14). The role of os-
teopontin in atherosclerosis is
unclear but is attributed to its
role as a mediator of inflamma-
tory response.
Biochemistry of OPG
OPG is a cytokine of the tumor
necrosis factor (TNF) receptor
superfamily and is classed as an
osteoclastogenesis inhibitory fac-
tor. Biochemically, OPG is a ba-
sic secretory glycoprotein com-
posed of 401 amino acid residues
with 7 distinct structural do-
mains. It exists as either a mono-
mer of 60 kDa or a disulfide
bond linked homodimer of 120
kDa (15). The homodimeric
form of OPG is biologically
more active than the monomeric
form. Although initial studies
were done with monoclonal an-
tibodies detecting only the ho-
modimeric form of OPG, more
ecent studies use the enzyme-linked immunosorbent assay
echnique to detect total serum OPG levels—monomeric,
omodimeric, and OPG bound to its ligands in the serum.
he amino terminal domains 1 through 4 are cysteine rich
nd confer osteoclastogenesis inhibitory properties (15).
omains 5 and 6 at the carboxy terminal end of the protein
ontain apoptosis-mediating death domain homologous
egions (15). Domain 7 contains a heparin-binding region
s well as a free cysteine residue required for disulfide bond
ormation and dimerization (15) (Fig. 1).
Figure 1 Structural Domains of OPG
Domains 1 through 4 are cysteine-rich domains and express features similar to th
6 contain 2 death domain homologous regions, similar to those found in the intra
ligand and tumor necrosis factor receptor 1. Domain 7 is a heparin-binding region
Abbreviations
and Acronyms
AAA  abdominal aortic
aneurysm
CAC  coronary artery
calcium
CAD  coronary artery
disease
EC  endothelial cell
MI  myocardial infarction
MMP  matrix
metalloproteinase
OPG  osteoprotegerin
RANK  receptor activator
of nuclear factor B
RANKL  receptor
activator of nuclear factor
B ligand
TNF  tumor necrosis
factor
TRAIL  tumor necrosis
factor-related apoptosis-
inducing ligand
VSMC  vascular smooth
muscle cellIn humans, the OPG gene is a single-copy gene extend-
ng over 29 kB of the genome in chromosome 8 and
ontains 5 exons (16). One major transcription initiation
egion is located upstream of the initiation ATG codon, and
other minor regions are noted further upstream.
PG/RANKL/Receptor Activator of
uclear Factor B (RANK) Axis and TRAIL
steoblasts are essential to the differentiation and prolifer-
tion of osteoclasts; together they play an important role in
one metabolism throughout life preserving the finely bal-
nced dynamics of bone formation and resorption, but the
xact nature of this regulatory control was not known until
he late 1990s (17).
RANKL is expressed in vivo by osteoblasts, stromal cells,
nd T lymphocytes (18). RANK is expressed on the surface
f osteoclast precursor cells such as monocytes, macro-
hages, and dendritic cells (19,20). Interaction of RANKL
ith RANK activates nuclear factor  (a transcription
actor) by degradation of IB protein by IB kinase; this
egradation of IB protein frees the nuclear factor B
omplex, which then translocates to the nucleus initiating
ranscription of specific genes required for differentiation of
steoclasts (21).
OPG is expressed in vivo by endothelial cells (ECs),
ascular smooth muscle cells (VSMCs), and osteoblasts.
ithin ECs, OPG is associated with von Willebrand factor
ithin secretory granules called Weibel-Palade bodies.
pon stimulation with TNF- or interleukin-1 in vitro,
he OPG-von Willebrand factor complex is secreted into
he surrounding growth medium. This complex is also
oted in human serum, indicating EC activation by proin-
ammatory cytokines as one of the possible sources of
irculating OPG in patients with active atherosclerosis (22).
OPG acts as a decoy substrate to RANKL and competes
ith RANK, inhibiting RANKL-RANK interactions (23).
cellular domains of other tumor necrosis factor (TNF) receptors. Domains 5 and
smic region of mediators of apoptosis such as TNF-related apoptosis-inducing
n unpaired cysteine residue requisite for disulfide bond formation.e extra
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May 11, 2010:2049–61 Osteoprotegerin and Cardiovascular Diseaselist of cells expressing OPG and various regulating
actors/cytokines/hormones influencing the expression of
PG are listed in Table 1. Binding of OPG to RANKL
revents the proliferation and differentiation of osteoclasts
nd consequently bone resorption. OPG/RANKL/RANK
lso play an important role in vascular biology and adaptive
mmunity. OPG has been demonstrated in normal arteries,
hereas RANK, RANK, and osteoclasts have been identi-
ed mainly in calcified arteries (23).
OPG has also been noted to bind to another member of
he TNF superfamily, TRAIL. TRAIL functions as a
omotrimer and is expressed as a type II transmembrane
rotein (24). The extracellular domain of this protein can be
leaved proteolytically from the cell surface to act as a
oluble cytokine. TRAIL acts by binding to 4 TRAIL
eceptors. Two of these receptors (TRAIL receptor 1/death
eceptor 4 and TRAIL receptor 2/death receptor 5) contain
ytoplasmic sequences homologous to the death domains of
as and tumor necrosis factor receptor 1 and are able to
ediate apoptosis via the caspase activation pathways.
RAIL receptor 3 and TRAIL receptor 4, along with
actors Regulating OsteoprotegerinTable 1 Factors Regulating Osteoprotegerin
Cell Type Cytokine/Hormone
Osteoprotegerin
Expression
Endothelial IL-1 1
IL-1 1
TNF- 1
Smooth muscle cells Estrogen 1
IL-1 1
TNF- 1
PDGF 1
bFGF 1
TGF- 2
BMP-2 2
Osteoblasts IL-1 1
IL-11 1
IL-18 1
TGF- 1
Vitamin D3 1
Estradiol 1
Parathyroid hormone 2
Parathyroid hormone–related
protein
2
PGE2 2
Glucocorticoids 2
Bone marrow stromal cells IL-18 1
TNF- 1
BMP-4 1
TGF- 1
IGF-1 2
IL-1 2
IL-6 2
IL-11 2
IL-17 2
FGF basic fibroblast growth factor; BMP bone morphogenic protein; IGF insulin-like growthp
actor; IL  interleukin; PDGF  platelet-derived growth factor; TGF  transforming growth factor;
NF  tumor necrosis factor.PG, are decoy receptors for TRAIL (25–27). ECs and
SMCs both express TRAIL receptors 1 and 2, but
ecombinant TRAIL conversely promotes proliferation and
urvival of these cells via the Akt and extracellular signal-
egulated kinase/mitogen-activated protein kinase path-
ays (28).
ole of OPG in Atherosclerosis
nd Vascular Calcification
nimal models. Selective deletion of OPG in mice results
n early-onset severe osteoporosis as well as significant
edial calcification of the aorta and renal arteries (17).
hen compared with OPG/ mice, OPG/ mice dis-
lay increased calcification of the aortic media, particularly
hen given a high dose of phosphate or vitamin D3. These
rteries are also the sites of endogenous OPG expression in
ormal arteries, raising the possibility of a protective role of
PG. This protective role of OPG is particularly important
or preventing vascular calcification occurring secondary to
dministration of warfarin and vitamin D3 (29). However,
nactivation of OPG in apoE knockout mice also resulted in
ugmented vascular calcification and increased size of ath-
rosclerotic lesions compared with OPG/ apoE/ mice
30). This observation lends further credibility to the argu-
ent regarding the protective role of OPG.
Investigating this protective role of OPG in arterial
alcification, Min et al. (31) observed that transgenic ex-
ression of OPG in OPG/ mice prevents the onset of
rterial calcification, whereas exogenous administration of
igh doses of recombinant human OPG in adult mice (4
eeks old) did not affect a reversal of the aortic calcification,
nderlining the importance of the timing of OPG delivery.
otably, OPG seems to prevent calcification but is not able
o reverse vascular calcification once it has occurred.
In a seminal study, Morony et al. (32) fed an atherogenic
iet to low-density lipoprotein receptor knockout mice and
ubsequently treated them for 5 months with recombinant
PG (fc-OPG) or vehicle. The group of mice treated with
c-OPG had a significantly lower percentage of calcified
laque but, interestingly, without any difference in the
umber or size of the atherosclerotic lesions. Plasma OPG
evels were measured in the vehicle-treated mice from the
ime of initiation of an atherogenic diet. A significant
ncrease in plasma OPG levels was noted in the first month
f starting the atherogenic diet. Over the course of the next
ew weeks, there was no further increase in the levels of
PG despite progression of atherosclerosis. There was also
o decrease in the tissue levels of expression of the inflam-
atory cytokines such as interleukin-6, interleukin-1,
NF-, and monocyte chemoattractant protein-1 in the
c-OPG–treated mice. This leads us to believe that OPG
rotects against atherosclerotic calcification and may be a
arker of the onset of atherosclerosis but not of itsrogression or its severity.
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Osteoprotegerin and Cardiovascular Disease May 11, 2010:2049–61Conversely, serum levels of RANKL dropped below the
aseline by 3-fold within a month of starting the diet.
ubsequently, increasing serum levels of RANKL were
hown to positively correlate with the number but not of
ize or area of atherosclerotic plaque lesions, whereas in-
reasing vascular tissue RANKL mRNA levels from the
econd month correlated significantly with number, size,
nd area of plaque lesions.
Despite the growing evidence, the actual role of OPG in
therosclerotic calcification remains speculative. The cells of
ascular origin suspected of osteogenic phenotypic transfor-
ation are adventitial myofibroblasts, pericyte-like calcify-
ng vascular cells, and VSMCs (33–35). In view of the
ubstantial role of VSMCs in atherosclerosis and intimal
alcification, it is likely that along with ECs, they are the
ain source of increased levels of circulating OPG noted in
ardiovascular disease.
A few of the possible explanations for the role of OPG in
nhibiting arterial calcification are as follow:
. RANKL is strongly expressed in the extracellular matrix
of vessels with calcified plaque lesions and very weakly in
the media in normal arteries (36). RANKL has been
shown to initiate osteogenic phenotypic transformation
of the VSMCs via the bone morphogenic protein 4
pathway (37) and increase alkaline phosphatase activity
(33). OPG, being a natural decoy receptor for RANKL,
inhibits this process and possibly arterial calcification as
well.
. Endothelial dysfunction leads to increased translocation
of the inflammatory cells from the lumen into the intima.
Increased production of proinflammatory cytokines such
as TNF- (38) and interferon gamma (39) by these cells
results in initiation of arterial calcification as well as
up-regulation of OPG expression in ECs and VSMCs,
possibly as a counterprotective measure.
. TRAIL is known to induce apoptosis of ECs and
VSMCs in atherosclerotic plaque lesions. Binding of
TRAIL to its decoy receptor OPG inhibits its proapop-
totic activity, reducing the number of foci for calcifica-
tion (27).
. Deficiency of B lymphocytes in ldlr/ mice resulted in
a significant increase in atherosclerotic lesions (p 
0.046) (40). OPG regulates B-cell maturation, and in an
OPG/ model, immature B cells are noted, which
could possibly have some direct role in regulating the
immune response in atherosclerosis (41).
uman studies. Contrary to the apparent protective role
f OPG observed in the animal models, there seems to be a
istinct relationship between serum levels of OPG and
everity of atherosclerosis in human studies. Some of the
linical studies conducted in humans and their principal
ndings are listed in Table 2.
ssociation of OPG with other cardiovascular risk factors.
few studies have explored the association between OPGevels and traditional cardiovascular risk factors (42,43). she only consistent direct association seems to be with
ncreasing age and duration of diabetes (44). There is no
onsensus on the association of other established cardiovas-
ular risk factors such as body mass index, serum low-
ensity lipoprotein, high-density lipoprotein, or systolic
ypertension.
Interestingly, premenopausal women (younger than 50
ears of age) had higher OPG levels than men (younger
han 50 years of age) (p  0.001), whereas serum OPG
evels were no different in post-menopausal women com-
ared with men (p  0.179) (45). We can thus conclude
hat there is a regulatory role for sex steroids in the
xpression of OPG. What this role is has seemingly evaded
efinition due to contradictory results from different studies.
ogers et al. (46) described a weak positive association of
lasma OPG levels with estradiol, whereas Khosla et al. (45)
howed that, in women, there is no significant association
ith either estradiol or testosterone. In men, one study
howed a negative correlation with levels of testosterone
45), whereas another (47) showed a positive correlation
ith testosterone levels.
PG and vascular disease. In human studies, a significant
ssociation between levels of circulating OPG and vascular
alcification has been described. Clancy et al. (48) reported
uch an association with the presence of abdominal aortic
alcification, a known risk factor in the development of
bdominal aortic aneurysms (AAAs). Subsequently, a
eakly significant association (p  0.04, r  0.20) was
ound with the progression of AAAs in a cohort of men
ith small AAAs followed for a period of 3 years with serial
ltrasound studies (49). This correlation persisted on mul-
ivariate analysis controlling for traditional risk factors such
s age, diabetes status, smoking, and lipid profile. The
esearchers also showed up-regulated OPG expression
ithin the media of AAA biopsy specimens and more
mportantly demonstrated an attenuated secretion of OPG
rom the AAA biopsy specimens incubated with irbesartan
n vitro, with the cytokine production being reduced by 50%
ithin 4 days.
In a subsequent study (50), increased expression of
ngiotensin II type 1 receptor in aortic smooth muscle cells
as observed in the presence of OPG. Human aortic
mooth muscle cells incubated with angiotensin II showed a
inear increase in OPG production. Reduced expression of
ngiotensin II type 1 receptor and tissue concentration of
PG and matrix metalloproteinase (MMP)-9 was noted
pon adding the peroxisome proliferator-activated receptor-
amma ligand pioglitazone in aortic smooth muscle cells
n vitro. Whether these results can be extrapolated to
rovide us with therapeutic targets in the management
AAs and/or a wider spectrum of cardiovascular disease
emains to be seen.
In a cross-sectional study, Ziegler et al. (51) reported a
ositive correlation between serum levels of OPG and
everity of peripheral artery disease, but there was no
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May 11, 2010:2049–61 Osteoprotegerin and Cardiovascular Diseasetatistically significant difference in OPG levels between
atients with documented peripheral artery disease and
ealthy controls. These findings were similar to those of
tudies Evaluating the Association Between OPG/RANKL/RANK aTable 2 Studies Evaluating the Association Between OPG/RAN
First Author (Ref. #) Target Population Study Des
Shin et al. (84) Type 2 diabetes Cross-sectional, n
Xiang et al. (83) Type 1 and 2 diabetes patients Prospective, n  5
n  86 (type 2)
Rasmussen et al. (113) Type 1 diabetes patients Cross-sectional, n
Avignon et al. (86) Asymptomatic patients with
type 1 and 2 diabetes
Cross-sectional, n
Anand et al. (44) Asymptomatic type 2 diabetes Prospective, n  5
Omland et al. (112) Patients presenting with acute
coronary syndromes
Prospective, n  8
Abedin et al. (114) General population (unselected) Cross-sectional, n
Sandberg et al. (56) Patients with unstable and
stable angina
Cross-sectional, n
Helske et al. (115) Patients with aortic stenosis Cross-sectional, n
Omland et al. (116) General population Cross-sectional, n
Kiechl et al. (117) General population Prospective, n  9
Semb et al. (64) General population (nested
case-control study)
Prospective, 951 c
1,705 controls
Kiechl et al. (65) General population Prospective, n  9
Crisafulli et al. (66) Patients with AMI (n  58),
asymptomatic CAD (n  52),
and normal controls (n  52)
Cross-sectional, n
MI  acute myocardial infarction; CAC  coronary artery calcium; CAD  coronary artery diseas
VESV  left ventricular end-systolic volume; OPG  osteoprotegerin; RANK  receptor activatorennisi et al. (52). pole of OPG and RANKL in the pathogenesis of
therosclerosis. The role of OPG in vascular disease
rompted investigators to try to unravel the intertwined
rdiovascular DiseaseANK and Cardiovascular Disease
Primary Outcome Measure Main Findings
FMAD as an indicator of
endothelial function
Increased OPG levels were associated
with endothelial dysfunction
indicated by decreased FMAD
1); Endothelial function measured
as FMAD pre- and post-
treatment with insulin
After 6 months of insulin therapy,
FMAD was significantly increased,
whereas serum OPG levels
decreased significantly
Cardiovascular disease
prevalence
Higher OPG levels associated with
cardiovascular disease, worse
kidney function, glycemic control,
and presence of nephropathy
Prevalence of silent
myocardial ischemia by
myocardial perfusion
imaging
OPG levels were independently
associated with presence of silent
myocardial ischemia
Presence of CAC and coronary
events
Serum OPG levels associated with
severity and progression of CAC
and short-term cardiovascular
events
Death, recurrent MI, HF
hospitalization, and stroke
During an 89-month follow-up, higher
baseline OPG levels were
associated with mortality and HF
hospitalization independent of
C-reactive protein and troponin
6 Prevalence of CAC and aortic
plaque
Higher quartiles of OPG were
independently associated with
prevalence of CAC and aortic
plaque
OPG levels in stable vs.
unstable angina
OPG was significantly higher in
patients with unstable angina than
in patients with stable angina
Prevalence of HF HF was significantly associated with
increasing levels of OPG that
decreased after valve replacement
5 Left ventricular structure and
function
Higher OPG levels were associated
with higher left ventricular mass
and thickness and lower LVEF in
male patients; higher LVESV and
lower LVEF in female patients
Progression of carotid
atherosclerosis and
cardiovascular events
Over a 10-yr follow-up, higher OPG
levels were associated with
severity and progression of carotid
atherosclerosis, vascular mortality,
and incident cardiovascular
disease
nd Coronary event Higher baseline OPG but not RANKL
levels were associated with
coronary events
Cardiovascular disease
incidence
Increasing serum RANKL levels were
independently associated with
increasing vascular risk but not
atherosclerosis
Serum OPG and RANKL levels
in the different groups
OPG levels were significantly higher
and RANKL levels significantly
lower in AMI patients compared
with asymptomatic CAD patients
and normal subjects
D  flow-mediated arterial dilation; HF  heart failure; LVEF  left ventricular ejection fraction;
ar factor B; RANKL  receptor activator of nuclear factor B ligand.nd CaKL/R
ign
 104
0 (type
 291
 465
10
97
 3,38
 100
 131
 2,71
15
ases a
09
 162athways by which the apparent proatherogenic action of
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Osteoprotegerin and Cardiovascular Disease May 11, 2010:2049–61PG in humans is mediated. Mangan et al. (53) demon-
trated a linear increase in expression of adhesion molecules
uch as E-selectin, vascular cell adhesion molecule, and
ntercellular adhesion molecule when human umbilical vein
ndothelial cells are incubated with increasing concentra-
ions of OPG and TNF- in vitro. This causes increased
inding of monocytes to these adhesion molecules on the
Cs before their migration into the vascular intima, a key
tep in the pathogenesis of atherosclerosis (54). Further-
ore, there were 47% more monocyte THP-1 cells bound
er 1,000 ECs when incubated with OPG and TNF-
ompared with no OPG, indicating its possible role in
ensitizing ECs to the actions of TNF- in vivo. In another
tudy, human umbilical vein endothelial cells activated by
xposure to TNF- secreted significant amounts of OPG
ut not RANKL into the surrounding medium in vitro (55).
One of the hypotheses suggests that the association of
ncreased OPG seen in cardiovascular disease is the result of
n incomplete compensatory mechanism that immediately
aises the question regarding the role of RANKL and its
eceptors in atherosclerosis and arterial calcification.
ANKL mRNA levels are low in normal vessels but are
uch higher within calcified atherosclerotic plaques as well
s thrombus of ruptured coronary plaque lesions, indicating
heir potential role in atherosclerotic plaque calcification
nd in plaque vulnerability and rupture (36,56). In the vessel
all, RANKL is likely expressed by ECs, smooth muscle
ells, T lymphocytes, and mast cells, with its target cell
embrane-bound receptor RANK being expressed on the
urface of macrophages and dendritic cells (23). In the
resence of RANKL, microvascular ECs are seen to pro-
ote adhesion and intimal migration of monocytes (57).
ffect of OPG and RANKL on plaque stability. In-
reased OPG levels and increased expression of RANKL on
lymphocytes and RANK on monocytes are noted in
nstable plaque lesions (56). OPG levels were significantly
igher in patients with unstable angina compared with
ealthy controls. In the same study, peripheral blood mono-
uclear cells were shown to have increased expression of
ANKL after a percutaneous coronary intervention, which
n essence is an iatrogenic plaque rupture. Interestingly,
ANKL significantly increased the activity of MMP in
SMCs in patients with unstable angina. OPG supposedly
eutralizes the effect of RANKL on induction of MMP
ctivity in VSMCs by inhibiting its binding to RANK.
lthough this is true at higher OPG/RANKL ratios, at
ower OPG/RANKL ratios, as are found in inflamed
issues, OPG enhances the MMP-inducing activity of
ANKL. Binding of OPG with RANKL possibly inhibits
he rapid clearance of RANKL from the serum, stabilizing
ts levels, thus seemingly augmenting its actions. This
henomenon has been observed with other soluble TNF-
eceptors and their ligands (58).
This is a significant finding because MMPs seem to play
crucial role in the degradation of matrix in atherosclerotic
laques, rendering them vulnerable to plaque rupture (59– h1). The clinical role of OPG and RANKL in atheroscle-
osis and plaque vulnerability is summarized in Figure 2.
linical utility of OPG and RANKL as biomarkers. In
iew of their considerable association with the prevalence
nd severity of CAD, there is significant interest in devel-
ping OPG and RANKL as biomarkers and probably as
herapeutic targets for vascular disease. Their clinical role is
urrently limited due to their expression by numerous types
f tissues in vivo. Identifying tissue isoforms of OPG/
ANKL will potentially increase their clinical utility as a
arker of CAD.
The ability of OPG to predict prevalence and severity of
AD was studied previously in a few studies with consistent
esults (42,62,63). The plasma levels of OPG were found to
e higher in patients with acute coronary syndrome com-
ared with those with stable angina or normal coronary
rteries (p  0.032). Serum OPG levels were associated
ith the severity of coronary stenosis and a modest corre-
ation was also noted with the number of diseased vessels
62,63). These studies highlight the possible prognostic
tility of OPG as a biomarker in a clinical setting. A
-ng/ml increase in serum OPG levels relates to an odds
atio of 5.2 (95% confidence interval: 1.7 to 16.0, p  0.01)
or the presence of CAD.
These findings have been further strengthened by the
esults of the EPIC (European Prospective Investigation
f Cancer)-Norfolk cohort, a longitudinal prospective
tudy exploring the relationship between OPG levels and
he risk of CAD (64). During the 6-year follow-up of
5,663 asymptomatic individuals with no history of
AD, a coronary event occurred in 951 participants.
hen these patients were compared with 1,705 age- and
ex-matched healthy controls free of coronary events,
ased on age and sex, baseline OPG levels were found to
e very good predictors of the development of CAD. Of
ote, there was also a linear relationship between serum
PG levels and the risk of CAD but no significant
ssociation has been noted in the levels of serum-soluble
ANKL and coronary event risk over the follow-up
eriod in the same cohort of patients.
In an earlier study by Kiechl et al. (65), plasma levels of
ncomplexed soluble RANKL were significantly associated
ith vascular events with an adjusted hazard ratio per unit
ncrease in level of RANKL being 1.27 (95% confidence
nterval: 1.16 to 1.4, p 0.001). This prognostic ability was
ndependent of the traditional cardiovascular risk factors as
ell as C-reactive protein, OPG, and carotid or femoral
therosclerosis as assessed by their intima-media thickness
nd the loge-transformed atherosclerosis score.
Another dimension to this complex process has been
dded by the finding of markedly lower levels of RANKL in
atients presenting with ST-elevation MI compared with
atients with stable CAD and age- and sex-matched
ealthy controls. Lower levels of uncomplexed RANKL
ave also been reported in patients with CAD compared
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May 11, 2010:2049–61 Osteoprotegerin and Cardiovascular Diseaseith those without CAD, but RANKL levels were not
ssociated with the severity of CAD (66,67).
It is possible that:
. OPG is just a more reliable marker of OPG/RANKL/
RANK axis activity than RANKL even though RANKL
plays a more central role in the pathogenesis of athero-
sclerosis and plaque instability. Measurement of TNF-
superfamily of cytokines is difficult due to their inherent
instability in biological fluids and their rapid clearance
from the body, whereas the soluble TNF receptors are
biologically more stable and also analytically more reli-
able. Production of TNF- induces the shedding of the
tumor necrosis factor receptors and closely reflects the
TNF- activity (i.e., the serum level of soluble TNF
receptors reflects the background inflammatory state as
the levels have been noted to increase significantly in
inflammatory diseases) (68).
. Assays of RANKL measure the levels of uncomplexed
RANKL exclusively, whereas those of OPG measure
total OPG levels in the serum (monomer, dimer, and
bound). If the hypothesis that RANKL plays a patho-
genic role in atherosclerosis as well as plaque instability
Figure 2 Role of OPG in Atherosclerosis
1. In the presence of proinflammatory cytokines, expression of osteoprotegerin (O
thelial cell adhesion molecules, helping in the transmigration of monocytes and lym
expression of receptor activator of nuclear factor B ligand (RANKL) and form vasc
ratios increase activity of matrix metalloproteinase. 4. Increased matrix metallopro
thickness of the fibrous cap, the erosion of which causes thrombus formation. IFNwere to be true, it would hold that as the levels of nRANKL increased in the serum, it would get bound to
OPG, its decoy receptor. The picture that emerges from
this would be that of low RANKL levels but higher
OPG levels in the serum.
The association of serum OPG levels with CAD seem
onsistent, but the same cannot be said for RANKL.
ore data from prospective studies are needed before a
learer hypothesis about the role of the OPG/RANKL/
ANK axis in CAD can be formulated and its clinical
tility considered.
RAIL, Atherosclerosis,
nd Cardiovascular Disease
he other ligand for OPG, TRAIL, also seems to
articipate significantly in atherosclerosis and cardiovas-
ular disease. Normal arteries do not show any immuno-
taining for TRAIL protein and TRAIL mRNA. In
rterial specimens of both Mönckeberg sclerosis and
therosclerosis, TRAIL was colocalized with OPG to the
argins of calcification. In atherosclerosis, apoptosis was
up-regulated in endothelial cells, which in turn increases the expression of endo-
ytes into the intima of the vessel wall. 2. The inflammatory cells up-regulate
mooth muscle cells (VSMCs). 3. RANKL along with OPG at lower OPG/RANKL
e (MMP) activity leads to degradation of the extracellular matrix and reduced
erferon; TNF  tumor necrosis factor.PG) is
phoc
ular s
teinas
 intoted in the intima surrounding foam cell accumulations
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eactivity was also noted, indicating its role in cellular
poptosis and atherosclerosis (69).
There seems to be considerable confusion regarding the
ole of TRAIL in atherogenesis and plaque destabilization.
ome studies suggest a role for TRAIL in increasing
nflammatory gene expression on ECs (70,71), whereas
thers have demonstrated its role in the down-regulation of
dhesion of monocytes to ECs (72). Similarly, there are
onflicting reports regarding its role in the survival of ECs
28,73). TRAIL also promotes the migration and prolifer-
tion of the VSMCs from the media into the intima of the
essel wall, a key step in the propagation of atherosclerosis
74), but also in maintaining the stability of the advanced
esion being the main source of the extracellular matrix
roteins and the fibrous cap.
In a small, cross-sectional study, Michowitz et al. (75)
emonstrated that the serum level of soluble TRAIL was
uch lower in patients with acute coronary syndrome (acute
oronary syndrome–MI/unstable angina) than in patients
ith either stable angina or normal coronary arteries (p 
.0001). There was no significant difference noted in the
evel of TRAIL in the stable angina patients as well as those
ith normal arteries, pointing to the possibility of a defining
ole for TRAIL in plaque destabilization.
These findings were reproduced recently with a signifi-
antly higher serum OPG/TRAIL ratio noted in patients
ith acute MI compared with those with unstable angina
nd those with no CAD (p  0.01) (76). Using competitive
nd point enzyme-linked immunosorbent assay in the pres-
nce of recombinant TRAIL and OPG, it was shown that
he levels of OPG and TRAIL were not influenced by the
resence of the other. Interestingly, a higher ratio of
aseline OPG/TRAIL was noted in patients in whom heart
ailure subsequently developed at 6-month follow-up,
ost-MI compared with those with no heart failure. Mea-
urement of OPG/TRAIL ratio seems to offer some indi-
ation regarding the severity of acute MI and short-term (6
onths to 1 year) prognosis.
It is difficult to formulate one cohesive, comprehensive
heory regarding the role of TRAIL in the initiation and
rogression of atherosclerosis as well as in plaque rupture.
e can postulate that activation of apoptosis by TRAIL in
n early plaque lesion is antiatherogenic by attempting to
educe the number of inflammatory cells and VSMCs
ithin the intima. The findings that TRAIL promotes
urvival of ECs (28) and improves nitric oxide production
77), strengthen this hypothesis. In advanced plaque,
RAIL is localized to the shoulder region of the plaque
75), which is most prone to rupture. In response to the
xidized low-density lipoprotein or proinflammatory cyto-
ines such as interferon gamma, TRAIL induces apoptosis
f VSMCs/ECs (78), lymphocytes (79), and macrophages
80), rendering the plaque prone to rupture. iPG, Diabetes, and CAD
t is well established that patients with diabetes have a
igher risk of accelerated atherosclerosis. One of the key
teps in initiation of atherosclerosis is endothelial dysfunc-
ion characterized by decreased endothelial nitric oxide
ctivity characterized by increased vascular production of
eactive oxygen species and decreased nitric oxide synthase
ctivity (81,82). In attempting to explain the role of OPG in
therosclerosis, the association of serum OPG levels with
arkers of endothelial dysfunction has been reported in
atients with type 1 and 2 diabetes (83,84). In response to
reatment with insulin for 6 months, OPG levels decreased
ignificantly, coupled with a significant improvement in
ow-mediated arterial dilation. This result seems to be
ontrary to the findings by Pritzker et al. (85), who
lucidated the role of OPG and TRAIL in microvascular
C survival.
In a prospective study, Anand et al. (44) demonstrated
he association between atherosclerotic plaque burden and
PG levels. In this study, 510 asymptomatic diabetic
atients had CAC scans and were followed over a period of
8  5 months after which a repeat scan was performed.
ncreased CAC scores were significantly associated with
igher plasma levels of OPG in a multivariate model
djusted for other risk factors, statin use, and duration of
iabetes (adjusted odds ratio: 2.84, p 0.01) (Fig. 3). OPG
evels were also significantly higher in subjects who experi-
nced a cardiovascular event during the follow-up (p 
.0001). In contrast, high-sensitivity C-reactive protein and
nterleukin-6 levels neither correlated with CAC score nor
redicted cardiovascular events in the short term.
These results were similar to those of Avignon et al.
86), who demonstrated the significant association of
PG levels and silent CAD, diagnosed by myocardial
erfusion imaging in patients with type 2 diabetes. In a
ultivariate analysis, OPG levels of 8 pmol/l were
hown to be independently associated with abnormal
yocardial perfusion imaging (odds ratio: 4.2, p 
.01) Interestingly, plasma OPG levels were significantly
ower in patients treated with thiazolidinediones. The
ndings were attributed to the role of OPG in EC
ysfunction (55) and the endothelial protective role of
hiazolidinediones (87,88).
These findings are of significant clinical importance. The
merican Diabetes Association recommends screening for
AD in patients with type 2 diabetes with 2 additional
ardiovascular risk factors with an exercise stress test. This
uideline encompasses a large population of diabetic pa-
ients. The ability to identify the subset of diabetic patients
t increased risk of silent CAD based on plasma OPG levels
ould be of enormous benefit in risk stratifying these
atients. Better risk stratification will allow more appropri-
te focus of resources and could also avoid unnecessary
nvestigations in a large segment of patients.
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n Chronic Kidney Disease
he life expectancy of patients with end-stage renal disease
s significantly reduced due to early-onset CAD accounting
or 50% of all causes of mortality (89). CAD and vascular
alcification develop faster in patients with chronic kidney
isease than in the general population (90). Apart from the
raditional cardiovascular risk factors, several nontraditional
isk factors specific to end-stage renal disease patients have
een identified for this accelerated atherosclerosis and vas-
ular calcification. The prevalence of chronic inflammation,
ltered mineral metabolism (higher serum Ca X phosphate
roduct), hyperhomocysteinemia, increased oxidative stress,
etuin A, matrix Gla protein, and OPG are some that have
een implicated (91–93). It is beyond the scope of this
eview to comment on the role of each of these factors.
Coronary artery and vascular calcification is strongly
ssociated with cardiovascular disease and mortality (94,95).
PG levels are significantly higher in patients with chronic
idney disease compared with age- and sex-matched con-
rols, and increasing OPG levels have a linear relationship
ith worsening renal function (96). Similar findings are
oted in patients with chronic kidney disease on hemodi-
lysis (97). In the study by Nitta et al. (98), 102 patients on
egular hemodialysis were assessed for aortic calcification by
noncontrast computed tomography scan. Serum OPG
evels correlated significantly with the presence and severity
f aortic calcification in a multivariate analysis.
In prospective studies, higher serum OPG levels are
ignificantly associated with cardiovascular events (99,100).
orena et al. (101) used receiver operator characteristic
urve analysis to obtain the cutoff level of OPG best able to
Figure 3 OPG and Prevalence of Coronary Artery Calcium
Box and whisker plots demonstrating the median and interquartile ranges of
osteoprotegerin (OPG) in patients with minimal, mild, moderate, severe, and
extensive coronary artery calcification. Circles  outliers (1.5 to 3 box lengths
from upper edge of box); asterisks  extreme outliers (3 box lengths). From
Anand et al. (44).redict the presence of significant coronary calcification. ahis was identified at 757.7 pg/ml with 91.7% sensitivity
nd 59% specificity.
It has been suggested that increased OPG levels in
hronic kidney disease patients could just be accumulation
ue to impaired renal clearance of OPG. The decrease in
PG levels within 14 days of renal transplantation supports
his hypothesis (102). It is also possible that OPG levels are
igher as a compensatory/protective mechanism against the
onfluence of the “perfect storm” of proatherogenic and
rocalcification factors seen in this group of patients or the
ersistent low-grade inflammation induces increasing OPG
xpression from vascular cells in a vicious cycle of
nflammation-endothelial dysfunction-atherosclerosis-
alcification.
ole of OPG in Left Ventricular Dysfunction
eft ventricular dysfunction is one of the key prognostic
ndicators of cardiovascular mortality and morbidity (103).
he role of TNF- in the development of left ventricular
ysfunction has come to the forefront in recent years
104,105). Up-regulated expression of members of the
ytokines of the TNF family, including TRAIL, by periph-
ral blood mononuclear cells in heart failure patients has
een reported (106). Similarly, inflammatory cytokines,
pecifically, plasma soluble TNF receptor 1, levels were
ound to be independent predictors of left ventricular
ypertrophy (107).
In a mouse model of heart failure, significantly increased
RNA expression of OPG was noted in both the ischemic
nd nonischemic myocardium compared with those without
eart failure. Human subjects with heart failure had signif-
cantly increased serum levels of OPG compared with
ealthy controls. Furthermore, there was a clear-cut rela-
ionship between New York Heart Association functional
lass, cardiac index, and N-terminal pro–B-type natriuretic
eptide levels with p values consistently0.01. Serum levels
f RANKL correlated in patients with New York Heart
ssociation functional class IV heart failure, but correlated
ell with the cardiac index (p  0.05) (108). The role of
ANKL/RANK and OPG in heart failure is attributed
artly to the induction in activity of MMP by RANKL in
uman fibroblasts (MMP-2 and -9 in particular), resulting
n matrix degradation, adverse ventricular remodeling, and
orsening myocardial function (109,110).
The prognostic utility of serum OPG levels in heart
ailure patients was investigated in 2 prospective studies
11,112). Ueland et al. (111) recruited a subset (n  234) of
atients from the original OPTIMAAL (Optimal Therapy
n Myocardial Infarction with the Angiotensin II Antago-
ist Losartan) cohort of patients with a known history of
I and left ventricular dysfunction. During a 27-month
ollow-up, there were 32 deaths (14%), and there was a
ignificant difference in baseline OPG levels in those who
urvived compared with those who experienced increased
ll-cause mortality and specific cardiovascular events (2.8
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ubsequent study, Omland et al. (112) followed a cohort of
97 patients with acute coronary syndrome for a median
eriod of 89 months. A total of 83 patients were hospital-
zed with heart failure during the follow-up. The baseline
evel of OPG correlated significantly with the incidence of
eart failure (Fig. 4) (hazard ratio for every 1-SD increase in
ogarithm-transformed level of OPG being 2, p  0.001).
his association remained significant on adjusting for con-
entional risk factors including left ventricular ejection
raction.
onclusions
onsiderable controversy still exists regarding the role of
PG/RANKL/RANK/TRAIL in cardiovascular disease.
here is as yet no hypothesis unifying the apparent dichot-
my in the nature of OPG/RANKL/TRAIL noted in
nimal and human studies. It is possible that serum OPG
evels are increased in response to the vascular insult and
ngoing process of inflammation within an atherosclerotic
laque lesion as the component of a complex compensatory
echanism, placing RANKL and/or TRAIL at the center
f the pathogenesis atherosclerotic plaque lesions.
We have also described various studies highlighting the
pparent proatherogenic role of increased OPG itself. It
eems that OPG plays a role right from EC activation in the
resence of proinflammatory cytokines to plaque instability
ith its inherent up-regulation of MMP activity. The serum
PG levels could probably indicate ongoing EC injury as
ell as activation of the VSMCs, which have been observed
n progressing plaque lesions. An increased OPG level could
e an indicator of a proinflammatory milieu responsible for
Figure 4 Increasing OPG Levels Post-Myocardial
Infarction Predict Long-Term Mortality
Baseline OPG levels were significantly associated with all-cause mortality at
median follow-up of 89 months. Hazard ratio for 1-SD increase in log trans-
formed OPG at baseline was 1.7 (95% confidence interval: 1.5 to 1.9, p 
0.0001). Comparing the first and fourth quartiles of OPG, the hazard ratio was
4.2 (95% confidence interval: 2.8 to 6.3, p  0.0001). From Omland et al.
(112). Abbreviation as in Figure 2.ropagation of atherosclerosis. OPG as a marker of inflam-
ation is supported by the reduction in expression of OPG
n response to insulin, angiotensin II receptor blockers, and
eroxisome proliferator-activated receptor-gamma ligands,
hich have all been shown to attenuate background inflam-
ation.
The more interesting theory is that OPG does indeed
ave a dichotomous role in humans. In healthy individuals,
he proatherogenic and antiatherogenic effects are being
eld in a fine balance, but in the face of persistent positive
nduction by various risk factors associated with congestive
eart disease, similar to the majority of immune mecha-
isms, the proatherogenic pathway becomes predominant to
he detriment of the subject.
Although the clinical prognostic utility of OPG seems to
e awhile away yet, it does hold a great deal of promise in
elping the clinician risk stratify patients with cardiovascu-
ar disease more accurately. It may come to pass that
easurement of a host of biomarkers such as OPG/
ANKL/TRAIL/OPN in combination may be recom-
ended to provide more robust and clinically relevant
nformation.
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